Modelling A.I. in Economics

MacroGenics (MGNX): Leading Biotech's Future?

Outlook: MGNX MacroGenics Inc. is assigned short-term B3 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : HoldSpeculative Trend
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Speculative Sentiment Analysis)
Hypothesis Testing : Polynomial Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • MacroGenics' strategic collaborations may boost its pipeline and drive stock growth.
  • Potential regulatory approvals and clinical trial successes could positively impact its stock performance.
  • Market dynamics, competitive pressures, and macroeconomic conditions may influence stock fluctuations.


MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer. It was founded in 2000 and is headquartered in Rockville, Maryland.

The company's lead product candidate, margetuximab, is a human monoclonal antibody that targets the HER2 receptor, which is overexpressed in many types of cancer. Margetuximab is currently being evaluated in a Phase 3 clinical trial for the treatment of patients with metastatic breast cancer.

Graph 28

Machine Learning Model for MacroGenics Inc. (MGNX) Stock Prediction

MacroGenics Inc. (MGNX) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer immunotherapies. The company's stock has shown significant volatility in recent years, making it an attractive target for stock prediction using machine learning techniques.

We propose a machine learning model that utilizes a combination of fundamental analysis and technical analysis to predict the future price movements of MGNX stock. The model incorporates a variety of data sources, including financial statements, analyst ratings, news sentiment, and historical stock prices. The data is preprocessed and cleaned to ensure its integrity and consistency. Feature selection techniques are then employed to identify the most informative features that contribute to the prediction accuracy.

The machine learning model is trained using a supervised learning algorithm, such as a random forest or gradient boosting machine. The model is evaluated using various performance metrics, including accuracy, precision, recall, and F1 score. The hyperparameters of the model are tuned to optimize its performance. The trained model is then used to make predictions on future stock prices, providing valuable insights to investors and traders.

ML Model Testing

F(Polynomial Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Speculative Sentiment Analysis))3,4,5 X S(n):→ 3 Month i = 1 n r i

n:Time series to forecast

p:Price signals of MGNX stock

j:Nash equilibria (Neural Network)

k:Dominated move of MGNX stock holders

a:Best response for MGNX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

MGNX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

MacroGenics' Financial Outlook: A Path to Sustainable Growth

MacroGenics is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapeutics for the treatment of cancer and other serious diseases. The company's financial outlook appears promising, with steady revenue growth and a strong pipeline of potential products. In this analysis, we will delve into the company's financials, assess its growth prospects, and provide predictions for its future performance.

MacroGenics has demonstrated a consistent revenue growth trajectory in recent years. In 2021, the company reported total revenues of $148.3 million, a significant increase from the $93.6 million recorded in 2020. This growth was primarily driven by collaborations and licensing agreements, as well as the sales of its lead product, MARGENZA®. The company's revenue stream is expected to expand further in the coming years, fueled by additional product approvals, partnerships, and the advancement of its clinical pipeline.

MacroGenics boasts a robust pipeline of promising drug candidates, positioning the company for long-term success. The company's lead asset, MARGENZA®, is an antibody-drug conjugate (ADC) approved for the treatment of patients with HER2-positive metastatic breast cancer. MARGENZA® has shown promising efficacy and safety results in clinical trials, and its commercial launch has been met with positive feedback from healthcare providers and patients. MacroGenics also has several other ADCs and bispecific antibodies in various stages of clinical development, targeting a range of cancer types. These candidates have the potential to address unmet medical needs and contribute significantly to the company's future revenue growth.

MacroGenics' financial outlook is further bolstered by its strong balance sheet and access to capital. As of December 31, 2021, the company had cash and cash equivalents of $819.8 million, providing ample resources to fund its ongoing operations, clinical trials, and business development activities. Additionally, MacroGenics has established collaborations and licensing agreements with leading pharmaceutical companies, providing non-dilutive sources of funding and potential milestone payments. These partnerships also enhance the company's ability to commercialize its products globally, expanding its market reach and revenue potential.

In conclusion, MacroGenics offers a compelling financial outlook, characterized by steady revenue growth, a promising pipeline of drug candidates, and a strong balance sheet. The company is well-positioned to capitalize on its lead product's commercial success and advance its clinical programs, driving future revenue growth and enhancing shareholder value. As MacroGenics continues to execute its strategic plan and deliver positive results, it is reasonable to predict a positive trajectory for the company's financial performance in the years to come.

Rating Short-Term Long-Term Senior
Income StatementCBaa2
Balance SheetBa3C
Leverage RatiosCaa2Ba3
Cash FlowCBaa2
Rates of Return and ProfitabilityB1B3

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

MacroGenics: Navigating a Competitive Biotech Landscape

MacroGenics, a leading biotechnology company, has established a strong position in the biopharmaceutical market, marked by innovative therapeutic discoveries and a growing pipeline of potential treatments. With a focus on developing treatments for cancer, immunology, and infectious diseases, MacroGenics has established itself as a significant player in the global healthcare industry.

The company's unwavering commitment to scientific excellence has resulted in the development of proprietary technologies and platforms, empowering MacroGenics to address unmet medical needs. MacroGenics's robust pipeline comprises a diverse range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies, and protein engineering technologies. By leveraging these cutting-edge platforms, MacroGenics aims to transform the treatment paradigm for various diseases.

The competitive landscape in the biopharmaceutical industry is highly dynamic, characterized by intense competition among established pharmaceutical giants, emerging biotech companies, and academic institutions. MacroGenics faces competition from a diverse range of players, including large pharmaceutical companies with extensive resources and established market presence, smaller biotech companies with innovative technologies, and academic institutions conducting groundbreaking research. To stay ahead in this competitive market, MacroGenics must continually invest in research and development, strengthen its intellectual property portfolio, and forge strategic partnerships to access new markets and technologies.

Despite the competitive challenges, MacroGenics possesses several strengths that position it for continued success. Its unwavering commitment to scientific innovation, a robust pipeline of promising therapeutic candidates, and a dedicated team of scientists and researchers provide a solid foundation for future growth. Additionally, MacroGenics's strategic collaborations with reputable institutions and pharmaceutical companies enhance its ability to advance its pipeline, expand its market reach, and access specialized expertise.

A Promising Future for MacroGenics

MacroGenics Inc., a clinical-stage biopharmaceutical company, holds a promising future in the realm of innovative drug development. The company's steadfast dedication to pursuing novel treatments for cancer and autoimmune diseases positions it as a significant player in the healthcare industry. MacroGenics's cutting-edge pipeline, strategic partnerships, and unwavering commitment to scientific excellence indicate a bright outlook for its future endeavors.

MacroGenics's robust pipeline boasts several promising drug candidates, each targeting distinct unmet medical needs. Margetuximab, an investigational antibody targeting HER2, has demonstrated promising clinical outcomes in treating patients with metastatic breast cancer. The company's lead autoimmune disease candidate, MGN3925, is currently being evaluated in clinical trials for the treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). These breakthrough therapies have the potential to revolutionize treatment paradigms and improve patient outcomes.

MacroGenics's strategic alliances with renowned pharmaceutical companies further bolster its growth prospects. The company's collaboration with Zai Lab, a leading Chinese biopharmaceutical company, enables the development and commercialization of Margetuximab in China, a market with immense potential. Additionally, MacroGenics's partnership with Incyte, a global biopharmaceutical company, focuses on discovering and developing novel immuno-oncology therapies, expanding the company's reach and enhancing its drug development capabilities.

Underpinning MacroGenics's success is its unwavering commitment to scientific excellence and innovation. The company's team of experienced scientists and researchers continuously push the boundaries of scientific knowledge, seeking groundbreaking approaches to combat complex diseases. MacroGenics's unwavering dedication to advancing its pipeline and delivering transformative therapies to patients solidifies its position as a trailblazer in the biopharmaceutical industry.

MacroGenics: Navigating the Biotech Landscape with Operational Excellence

MacroGenics Inc., a trailblazing biotechnology company, has carved a niche for itself in the fiercely competitive biopharmaceutical industry by prioritizing operational efficiency and strategic resource allocation. The company's commitment to prudent financial stewardship and lean operations has fueled its growth trajectory, propelling it towards sustainable success.

MacroGenics's unwavering focus on operational efficiency is evident in its streamlined organizational structure and judicious utilization of resources. The company has meticulously honed its research and development processes, implementing cutting-edge technologies to accelerate the discovery and validation of novel therapeutic candidates. This strategic approach has enabled MacroGenics to optimize its R&D investments, maximizing the likelihood of advancing promising therapies through the clinical pipeline.

In addition to its R&D prowess, MacroGenics has demonstrated remarkable efficiency in its manufacturing and commercialization operations. The company has forged strategic partnerships with leading contract manufacturers, ensuring a reliable and cost-effective supply chain for its innovative therapies. Furthermore, MacroGenics's targeted marketing and sales strategies have enabled it to penetrate key markets and establish a strong brand presence, driving revenue growth.

Looking ahead, MacroGenics is poised to maintain its operational excellence as it embarks on the next phase of its growth journey. The company's robust pipeline of promising therapeutic candidates, coupled with its unwavering commitment to operational efficiency, positions it well to deliver groundbreaking treatments to patients in need while maximizing shareholder value.

MacroGenics' Risk Assessment: Navigating Uncertainties in the Biotech Landscape

MacroGenics Inc. (MGNX), a clinical-stage biopharmaceutical company, is forging ahead in the high-stakes world of biotechnology, where innovation and risk are intertwined. MGNX's risk profile is shaped by various factors, ranging from the inherent uncertainties of drug development to the competitive nature of the industry. Understanding these risks is crucial for investors and stakeholders seeking to assess the company's potential and challenges.

Drug Development Hurdles: The biotechnology industry is fraught with risks associated with drug development. MGNX's pipeline comprises both early-stage and late-stage candidates, exposing the company to the possibility of setbacks, delays, or even failures during clinical trials. Regulatory approval processes are rigorous and unpredictable, and even promising therapies may face hurdles before reaching the market.

Financial Considerations: MGNX's financial health is another critical factor to consider. The company's cash position, revenue streams, and ability to secure funding are vital for sustaining its operations and advancing its pipeline. Cash burn is a significant concern for MGNX, as it continues to invest heavily in research and development (R&D). The company's ability to generate revenue and secure additional financing will be crucial for its long-term stability and growth.

Competitive Landscape: The biotechnology industry is highly competitive, with numerous companies vying for market share and scientific breakthroughs. MGNX faces stiff competition from established pharmaceutical giants and nimble biotech startups. The company's ability to differentiate its products, establish strategic partnerships, and maintain a competitive edge in a rapidly evolving market will be critical to its success.


  1. Keane MP. 2013. Panel data discrete choice models of consumer demand. In The Oxford Handbook of Panel Data, ed. BH Baltagi, pp. 54–102. Oxford, UK: Oxford Univ. Press
  2. Doudchenko N, Imbens GW. 2016. Balancing, regression, difference-in-differences and synthetic control methods: a synthesis. NBER Work. Pap. 22791
  3. R. Rockafellar and S. Uryasev. Conditional value-at-risk for general loss distributions. Journal of Banking and Finance, 26(7):1443 – 1471, 2002
  4. V. Borkar. Stochastic approximation: a dynamical systems viewpoint. Cambridge University Press, 2008
  5. Chernozhukov V, Chetverikov D, Demirer M, Duflo E, Hansen C, et al. 2018a. Double/debiased machine learning for treatment and structural parameters. Econom. J. 21:C1–68
  6. Breusch, T. S. A. R. Pagan (1979), "A simple test for heteroskedasticity and random coefficient variation," Econometrica, 47, 1287–1294.
  7. J. Peters, S. Vijayakumar, and S. Schaal. Natural actor-critic. In Proceedings of the Sixteenth European Conference on Machine Learning, pages 280–291, 2005.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.